Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.79 EUR | -2.72% | -1.65% | +24.31% |
04-12 | Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... | |
04-12 | NFL Biosciences: successful capital increase | CF |
Business Summary
At the end of 2022, the company has one product in phase II/III clinical development (NFL-101) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol reduction).
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bruno Lafont
FOU | Founder | - | 31/08/06 |
Ignacio Faus
CEO | Chief Executive Officer | - | 18/05/21 |
Guillaume Audema
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Yannick Plétan
BRD | Director/Board Member | - | 18/05/21 |
Ignacio Faus
CEO | Chief Executive Officer | - | 18/05/21 |
Bruno Lafont
FOU | Founder | - | 31/08/06 |
Francis Ahner
BRD | Director/Board Member | - | 18/05/21 |
Michel Huc
BRD | Director/Board Member | - | 18/05/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 7,606,769 | 5,182,266 ( 68.13 %) | 0 | 68.13 % |
Company contact information
NFL Biosciences SAS
199 rue Hélène Boucher
34170, Castelnau-le-Lez
+33 4 11 93 76 67
http://www.nflbiosciences.comSector
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+24.31% | 15.96M | |
-1.22% | 103B | |
+8.28% | 101B | |
+4.40% | 23.07B | |
-11.97% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.46% | 16.94B | |
+6.63% | 14.07B | |
+39.12% | 12.35B |
- Stock Market
- Equities
- ALNFL Stock
- Company NFL Biosciences